TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: DSMQ Health Care Use Domain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VQ11 Quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Renal damage associated with Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Differences in predicted refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extra-cellular volume fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological Indicator (Lactate) for 40km at 70%FTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological Indicator (Blood Glucose) for 40km at 70%FTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Perceived Exertion for 40 km at 70% FTP
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Psoriasis Area Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-eruptive breakdown / dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: App onboarding rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wysa app engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: App satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: App Acceptability and experiences of usage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Metacognitive beliefs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rumination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive care experience scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Situation Continuous Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Overall Motivation for Treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Change in Weekly Motivation Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Confidence to Engage in Treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nasal Polyps Score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Congestion Score (NCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change of TKV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: symptomatic intracerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: major systemic bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of gene methylation classifiers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative and positive predictive value of gene methylation classifiers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Orexin A promoter methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orexin B promoter methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of delayed adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence of gene modified T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Glucose and HbA1c Levels in Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kidney Function Tests in Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Stable Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Edinburgh Post-natal Depression Scale (EPDS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Y-Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Countermovement Jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triple Hop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Testing and Vaccine Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COVID-19 Mistrust Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19 Testing Accessibility - Ease of Access
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Treatment Discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction from Baseline in Weekly Average of Daily Itch Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reporting penicillin allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Recruitment Success Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intervention Completion Success Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Data Collection Success Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Adverse events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Disease safety (flare)
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity after MTX discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity after MMF discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Recurrence Rate of Hypoglycemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hand Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with minimal residual disease negative complete remission (MRD-CR) or MRD-complete remission with incomplete count recovery (Cri)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants reporting PrEP initiation by 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening in the clinical reference test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titer of serum RSV A and B neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient no-shows
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Conditional weight gain z-score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Attachment & Removal Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hepatic cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topographic outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demarcation line depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrences of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologic progression-free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of participants who complete audiologic follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Model-Based Annualized Bleeding Rate for Treated Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Calculated Annualized Bleeding Rate for Treated Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median Calculated Annualized Bleeding Rate for Treated Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnosis of therapy-relevant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concomitant cardiac findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relactation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of mothers' breastfeeding self-efficacy level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Determination of amount of breast milk the baby receives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Elevated cTnI Levels at Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Elevated cTnI Levels at Day 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HF rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measurement of craniovertebral angle (CVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of neck pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of cervical range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of treatment emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidences of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete median sternotomy wound cutaneous dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Negative predictive value for pathologic complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the number of monthly migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of homogeneous patient groups at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H2S content in uterine arterial smooth muscle circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of children developing long covid
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of IAD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Energy Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Reported Treatment Burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Home and Community Services Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intensity of pain in the fingers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sensitivity of polyps identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: specificity of polyps identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of mitochondrial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant sleep position in the previous two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant sleep location in the previous two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft bedding use in the previous two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacifier use in the previous two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastmilk feeding in the previous two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosing Schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-neoplastic Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Preeclampsia with or without severe features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pregnancy Loss
Endpoint domain: Mortality/survival
Primary endpoint: Change in 24-hour average Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of Clear (0) or Almost Clear (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in physical frailty measured by SPPB scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lasting return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Intra-prostatic YAP-mediated T-reg dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major Response Rate (MRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Serious Adverse Events and Suspected Unexpected Serious Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Clinically Significant Changes from Baseline - Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Minimal-residual disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients able to swallow ≥ 40 capsules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (CR)/Complete Response with Incomplete Hematologic Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AEs) associated with the ruxolitinib-containing regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Tolerated a Single Dose of Peanut Protein Without Dose-limiting Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of successful US-guided breast biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in skeletal muscle EPA and DHA content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiological status of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Terminal phase half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single dose Cmax (Maximum plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single dose AUCtau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple dose Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple dose AUCtau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to treatment failure or death
Endpoint domain: Mortality/survival
Primary endpoint: FVC (%-percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1/FVC (percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory muscle test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Target vessel patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of all TEAEs, TESAEs, AESIs, and NOCDs
Endpoint domain: Adverse events/effects
Primary endpoint: Study discontinuations prior to Day 151 post 2nd dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and severity of symptom events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of symptom events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Total Hip Areal Bone Mineral Density (aBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in percent correct for the /ɹ/ sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of photonumeric volume of eyebags
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of expanded CD4 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and location of autofluorescent parathyroid glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: vital status of severe trauma patients
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with at least one new ACL injury
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment emergent serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Catastrophizing Scale for Children (PCS-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire (PHQ)-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS short form for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS v1 short form for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of AEs of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change in epistaxis duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global symptom change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in N-level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Corsi span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Inhibitory Control Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Everyday Memory Questionnaire Revised
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in sit and reach test measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Oswestry index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Assessment of Motor and Process Skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom from Stricture Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total antioxidant capacity (TAC) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor necrosis factor alpha (TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recruitment Benchmark
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient global impression of change following treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in active cervical spine range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with Cytokine Release Syndrome/Infusion Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrasonographic Diaphragm Thickness Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fibromyalgia diagnostic criteria-Widespread pain index (WPI)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Perianal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes